ALISKIREN, OBAT ANTIHIPERTENSI BARU DENGAN MEKANISME PENGHAMBAT RENIN

  • Diana Holidah
Keywords: Aliskiren, hypertension, renin

Abstract

Hypertension is a chronic disease with a prevalence reaching 1 billion people around the world. Hypertension is the major treatable risk factor for cardiovascular disease, which remains the leading cause of death in the industrialized world. Despite the risks associated with the condition, the majority of patients with hypertension across the world do not have their blood pressure (BP) controlled to recommended target levels. RAAS is a main target, although, in total inhibition of RAAS can not be obtained with ACEI and ARB class of drugs because of the feedback mechanism. As a solution, we could inhibit the early stages of the mechanism, that is renin. Previous studies have indicated that the renin inhibitor class of drugs effective as antihypertensive and well tolerated, both as monotherapy and in combination with other drugs. Based on researched to aliskiren and the success of antihypertensive drug class of ACEI and ARB in reducing morbidity and mortality in patients with hypertension, it is rational if the expected drug classes like renin inhibitor aliskiren would provide the same benefits. Whether the benefits are equal, larger or even smaller than another RAAS inhibitor, we needed long research to find supporting data.

Key word: Aliskiren, hypertension, renin

 

ABSTRAK

Hipertensi merupakan salah satu penyakit kronis dengan prevalensi mencapai 1 milyar jiwa di seluruh dunia. Hipertensi yang menginduksi penyakit kardiovaskular merupakan penyebab utama kematian di dunia. Pengaturan tekanan darah hingga optimal masih sulit untuk dicapai di semua Negara. RAAS merupakan target utama, walaupun begitu, penghambatan RAAS secara total tidak dapat diperoleh dengan penggunaan obat golongan ACEI dan ARB karena adanya mekanisme umpan balik. Sebagai solusinya, dapat dilakukan penghambatan pada tahap awal dari mekanisme tersebut yaitu pada renin. Penelitian sebelumnya sudah mengindikasikan bahwa obat golongan renin inhibitor efektif sebagai antihipertensi dan dapat ditoleransi dengan baik, baik sebagai monoterapi maupun dikombinasi dengan obat lain. Berdasarkan penelitian yang sudah dilakukan terhadap aliskiren serta keberhasilan obat antihipertensi golongan ACEI dan ARB dalam menurunkan angka morbiditas dan mortalitas pada penderita hipertensi, maka sangat rasional jika diharapkan obat golongan renin inhibitor seperti aliskiren akan memberikan manfaat yang sama. Apakah manfaat tersebut sama, lebih besar atau justru lebih kecil daripada yang ditunjukkan oleh inhibitor RAAS yang lain, maka diperlukan penelitian lain yang panjang untuk mencari data pendukung.

Kata kunci: Aliskiren, hipertensi, rennin

Downloads

Download data is not yet available.

References

1.Muller, D.N.; & Luft, F.C. 2006,Direct Renin Inhibition with Aliskiren in Hypertension and
Target Organ Damage, Clin. J. Am. Soc. of Nephrology, 1: 221–228
2.Saseen, J.J.; & Carter, B.L.2005,Hypertension, inDiPiro J.T., Pharmacotherapy a Pathophysiologic Approach, McGraw-Hill
3.Nafrialdi. 2007,Hipertensi, in Farmakologi dan Terapi, Departemen Farmakologi dan Terapi, Fakultas Kedokteran UI, Jakarta
4.Sukandar, E.Y.; Andrajati, R.; Sigit, S.i.; Adyana, I.K.; Setiadi, A.P.; & Kusnandar. 2008,
ISO Farmakoterapi, ISFI penerbitan. Jakarta
5.Gradman, A.H.; Schmieder, R.E.; Lins, R.L.; Nussberger, J.; Chianh, Y.; & Bedigian, M.P.
2005,Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-dependent Antihypertensive Efficacy and Placebo-like Tolerability in Hypertensive Patients, Circulation, 111, 1012-1018
6.Vaidyanathan, S.; Jermany, J.; Yeh, C.; Bizot, M.N.; Camisasca, R. 2006,Aliskiren, a Novel
Orally Effective Renin Inhibitor, Exhibits Similar Pharmacokinetics and Pharmacodinamics in Japanesse and Caucasian Subjects, British J. Clin. Pharmacology, 62:6, 690-698
7.Jan Danser, A.H.; Charney, A.; Feldman, D.L.; Nussbenger, J.; Kisner, N.; & Hollenberg, N.
2008,The Renin Rise with Aliskiren, its Simply Stoichiometry, Hypertension, vol 51 e27-e28
8.Kushiro, T.; Itakura, H.; Yoshihisa, A.; Gatau, H.; Terdo, S.; & Keefe, D.L. 2006,Aliskiren, a
Novel oral renin Inhibitor, Provides dose dependent Effecacy and Placebo like Tolerability in
Japanese Patients with Hypertension, Hypertention Research, vol 29 no 997-1005
9.Oparil, S.; Yarrowa, S.; Patel, S.; Fang, S.; Yarrows, S.; Zhang, J.; & Zlatan, A. 2009,Efficacy and Safety of Combined use of Aliskiren and Valsartan in patient with Hypertention; Randomised double Blind Trial, The Lancet, vol 370 p 221-229
10.O’brien, E.; Barton, J.; Nussberger, J.; Mulcany, D.; Jensen, C.; Dicker, P.; & Stanton, A.
2007,Aliskiren Reduces Blood Pressure and Supresser Plasma Renin Activity in Combination with Thiazide Diuretics, an Angiotensin Converting Enzim Inhibitor or an
Angiotensin Receptor Blocker, Hypertension,vol 49 p 276-284
11.Jordan, J.; Engeli, S.; Boye, S.W.; Le Broton, S.; & Keefe, D.L. 2007,Direct Renin Inhibition
With Aliskiren in Obese Patient with Arterial Hypertension, Hypertension, vol 49 p 1047-1055
Published
2011-12-31
How to Cite
Holidah, D. (2011). ALISKIREN, OBAT ANTIHIPERTENSI BARU DENGAN MEKANISME PENGHAMBAT RENIN. Journal of Tropical Pharmacy and Chemistry, 1(3), 235-246. https://doi.org/10.25026/jtpc.v1i3.34